Navigation Links
Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
Date:5/15/2013

60; The decrease was the result of decreased expenses related to the development of Excellagen, partially offset by increased costs associated with the Company's ongoing Generx ASPIRE study.  After taking into account a one-time expense totaling $100,000 of product and testing in association with Excellagen, to validate higher level production volumes, and related cost efficiency improvements, research and development expenses in the first quarter 2103 were overall reduced by 46% when compared to the first quarter 2012.  Selling, general and administrative expenses for the three-month period ended March 31, 2013 were $1.7 million, compared to $1.5 million for the same period in 2012.  The increase was primarily due to costs associated with To Go Brands operations. 

For the three months ended March 31, 2013, the Company reported a lower net loss of $2.2 million, or $(0.02) per share, when compared to a net loss of $2.6 million, or $(0.02) per share for the three months ended March 31, 2012.  The decrease in net loss was due to cost reductions and increased sales revenue. 

As of March 31, 2013, the Company had $0.4 million in cash and cash equivalents and working capital was $0.8 million.  Net cash used in operating activities was $2.1 million for the three months ended March 31, 2013, compared to $2.2 million for the three months ended March 31, 2012.  The decrease in net cash used in operating activities was due primarily to an increase in product sales, and decreases in testing and process validation costs for the initial inventory of Cardium's Excellagen wound care product. 

As reported on April 5, 2013, subsequent to the end of the quarter, the Company raised an additional $2.2 million in net proceeds in a preferred stock financing.  In April 2013, Cardium entered into a securities purchase agreement with one of its institutional investors pursuant to which it agreed to sell to the investor
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Cardium Announces Generx Publication In Molecular Therapy
2. Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting
3. Cardium Presents Year-End 2012 Financial Results And Recent Developments
4. Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance
5. Cardium Receives ISO Certification for Excellagen
6. Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum
7. Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments
8. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
9. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
10. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
11. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories ... active pharmaceutical ingredients (APIs), complex intermediates ... located in 85 countries, today announced financial results ... 2015, ended June 30, 2014. "Neuland,s ... work flow re-prioritization to accommodate certain customer needs, ...
(Date:8/1/2014)... 1, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep ... Industry" and "2014 Deep Research Report on Global ... its research database. Photo - ... Research Report on Global and China Potassium Nitrate ... on China and Global ...
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
Breaking Medicine Technology:Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30
... ADA,s 2009 Convention -- When Shawnae Jebbia won the Miss ... fairytale career. She appeared at events throughout the world, worked ... Shawnae,s world unexpectedly changed when she was diagnosed with hearing ... she had a difficult time understanding and accepting the sudden ...
... Oct. 29 Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... , Sales in local currency declined by 12% in ... negative currency impact. , Net earnings per diluted ... third quarter of 2008. Adjusted EPS was $1.36, a 6% ...
Cached Medicine Technology:Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 13
(Date:8/1/2014)... (HealthDay News) -- The U.S. Food and Drug Administration ... Jardiance, to help fight type 2 diabetes. ... existing treatment regimens to control blood sugar levels in ... of the Office of Drug Evaluation II in the ... an agency statement. The FDA also recommended that ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 As ... on behalf of women who allegedly experienced the spread ... morcellators in gynecological surgeries, Bernstein Liebhard LLP notes the ... a number of power morcellators marketed by its Ethicon, ... from The New York Times, some critics of the ...
(Date:8/1/2014)... 2014 As AndroGel lawsuits and testosterone ... E. Johnson, Jr. has been appointed as co-lead counsel ... testosterone medications. Since the Fall of 2013, Ron and ... diligently to investigate and prosecute the claims of men ... clots as a result of taking testosterone. As a ...
(Date:8/1/2014)... The American Telemedicine Association (ATA) ... and Peter Welch (D-VT), for their latest actions ... Act of 2014, which improves telemedicine coverage in ... improve healthcare access and affordability using telecommunications technology," ... "These cost-saving provisions are critical to improve telehealth ...
(Date:8/1/2014)... Hot off the presses after the announcement of ... World’s Best Awards by Travel + Leisure , The ... Relaxation Day (technically August 15). , The Lodge at ... help guests celebrate relaxation throughout the month of August. ... wellness to carve out time to relax and unwind. ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4
... than 500 Workers, WASHINGTON, May 16 ... the Greater Portland, Oregon and,Vancouver, Washington area have ... are pleased that these workers are now covered ... and a secure retirement,future," said Teamsters General President ...
... fibroids located just beneath the lining of the uterus (submucosal) ... uterine artery embolization (UAE) but usually dont cause major complications, ... 49 patients with 140 fibroids who underwent an MRI examination ... these were submucosal. Of these, 33% migrated to the endometrial ...
... Kwon Presents Urban Health Institute with 10,000 Sensual O Condom ... Mansion Fundraiser, LOS ANGELES, May 16 On Saturday, ... known best for his hit song "Everybody in the Club,Gettin, ... Sensual O Vibrating Condom Packs worth over $50,000. The donation ...
... May 16 Huntsworth plc (LSE: HNT), "the Group",a leading international public relations and healthcare ... the first quarter 2008 (the period,ending March 31, 2008)., The statement follows below., ... ... Interim Management Statement, ...
... Nationwide,Health Properties, Inc. (NYSE: NHP ) announced ... Vice President and Senior Investment Officer. "Dave,has made ... several years as,evidenced by our strong investment growth ... over $1 billion in accretive,investments for NHP, leveraging ...
... for at least a year or two, , , FRIDAY, ... people with type 1 diabetes live insulin-free for at ... longer-term improved metabolic control even after people have to ... glucose monitoring systems, researchers from the University of Miami ...
Cached Medicine News:Health News:Everybody in the Club Scream O! 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:David M. Boitano Promoted to Senior Vice President 2Health News:Islet Cell Transplants Aid Type 1 Diabetics 2Health News:Islet Cell Transplants Aid Type 1 Diabetics 3
Scleral blades designed for trabeculectomy and groove type incisions, scleral standard USA size....
Fechtner Trabeculectomy Marker...
... for Nystagmus when rotated at 8-10 ... 8" diameter. Light weight drum of ... effortless spin mechanism. For use 24 ... both Adult and Pediatric Drums that ...
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Medicine Products: